{"id":34571,"date":"2026-02-20T17:56:00","date_gmt":"2026-02-20T12:26:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=34571"},"modified":"2026-03-06T15:26:58","modified_gmt":"2026-03-06T09:56:58","slug":"til-therapies-for-solid-tumor-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/til-therapies-for-solid-tumor-treatment","title":{"rendered":"Tumor\u2011Infiltrating Lymphocyte (TIL) Therapies: Redefining Cell Therapy for Solid Tumors"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d72c2036da7\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d72c2036da7\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/til-therapies-for-solid-tumor-treatment\/#Iovance_Brings_TILs_to_Market\" >Iovance Brings TILs to Market<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/til-therapies-for-solid-tumor-treatment\/#The_Emerging_TIL_Pipeline_Next%E2%80%91Generation_Innovation\" >The Emerging TIL Pipeline: Next\u2011Generation Innovation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/til-therapies-for-solid-tumor-treatment\/#Recent_Developments_in_the_TIL_Therapy_Segment\" >Recent Developments in the TIL Therapy Segment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/til-therapies-for-solid-tumor-treatment\/#Conclusion_A_New_Era_for_Solid_Tumor_Cell_Therapy\" >Conclusion: A New Era for Solid Tumor Cell Therapy<\/a><\/li><\/ul><\/nav><\/div>\n\n<p><strong>Summary&nbsp;<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><em>TIL therapy marks a major shift in solid-tumor immunotherapy, offering an effective approach where CAR-T strategies have struggled, broadening options beyond PD-1 and BRAF\/MEK inhibitors for metastatic melanoma, and driving extensive clinical evaluation across NSCLC, HNSCC, CRC, pancreatic, prostate, cervical, and other cancers.&nbsp;<\/em><\/li>\n\n\n\n<li><em>Iovance\u2019s AMTAGVI (lifileucel) has emerged as the first approved personalized TIL treatment, earning accelerated FDA authorization for advanced melanoma after PD-1 therapy.&nbsp;<\/em><\/li>\n\n\n\n<li><em>Its approval has catalyzed a surge in competitive development, with companies such as Obsidian Therapeutics (OBX-115), KSQ Therapeutics (KSQ-001EX and KSQ-004EX), Curacell Holding (CC-38), Intima Bioscience (CISH-inactivated TIL), and others advancing next-generation TIL programs.<\/em><\/li>\n\n\n\n<li><em>At the same time, Iovance is broadening its own TIL pipeline, including candidates like LN-145 and IOV-4001, while pursuing combination regimens and expanding into new therapeutic areas such as NSCLC and endometrial cancer.<\/em><\/li>\n\n\n\n<li><em>The TIL therapy market across the 7MM was valued at roughly USD 103 million in 2024. It is projected to grow at a CAGR of 37%, driven by rising disease awareness, improvements in diagnostic practices, and the introduction of new therapies.<\/em><\/li>\n<\/ul>\n\n\n\n<p>Over the past decade, cell-based immunotherapies have revolutionized the treatment landscape for hematologic malignancies. In contrast, solid tumors have remained far more resistant to curative cellular approaches. Tumor-infiltrating lymphocyte (TIL) therapies are now emerging as one of the most promising solutions to this challenge, offering a highly personalized strategy that leverages a patient\u2019s own immune system to target cancer.<\/p>\n\n\n\n<p>TIL therapy marks a major shift in solid-tumor immunotherapy, delivering effective tumor targeting where CAR-T therapies have struggled, extending treatment options beyond PD-1 and BRAF\/MEK inhibitors in metastatic melanoma, and enabling broad clinical exploration across NSCLC, HNSCC, CRC, pancreatic, prostate, cervical, and other solid tumors.<\/p>\n\n\n\n<p>In 2024, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/tumor-infiltrating-lymphocytes-til-therapies-epidemiology-forecast\">selected indications for TIL therapies<\/a> accounted for <strong>4.5 million<\/strong> cases across the 7MM, a number expected to rise by 2034. Prostate cancer represents the largest opportunity for TIL therapy, followed by NSCLC, driven not only by high incidence but also by low tumor immunogenicity, poor response rates to checkpoint inhibitors, and limited effective therapies after standard of care, highlighting a substantial unmet medical need.<\/p>\n\n\n\n<p>With the first FDA approval of a TIL product, rapid clinical development across multiple tumor types, and increasing commercial momentum, TIL therapies are transitioning from experimental concepts to a foundational pillar in the treatment of solid tumors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-iovance-brings-tils-to-market\"><span class=\"ez-toc-section\" id=\"Iovance_Brings_TILs_to_Market\"><\/span><strong>Iovance Brings TILs to Market<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The TIL therapy field reached a historic inflection point in 2024 when the US FDA approved <strong>AMTAGVI (lifileucel)<\/strong>, developed by <strong>Iovance Biotherapeutics<\/strong>, as the first TIL\u2011based therapy and the first autologous cell therapy approved for a solid tumor. AMTAGVI is an autologous T-cell therapy derived from a patient\u2019s own tumor and is approved for adults with unresectable or metastatic melanoma who have previously received a PD-1 inhibitor, and, for those with a BRAF V600 mutation, prior treatment with a BRAF inhibitor with or without a MEK inhibitor.&nbsp;<\/p>\n\n\n\n<p>This <a href=\"https:\/\/www.delveinsight.com\/report-store\/tumor-infiltrating-lymphocyte-til-therapies-market-forecast\">approval of TIL-based therapy<\/a> was granted under the FDA\u2019s accelerated approval pathway based on overall response rate (ORR), with continued approval dependent on confirmation of clinical benefit in follow-up studies. By the end of 2024, more than <strong>200 patients<\/strong> had received AMTAGVI during the first three quarters of its commercial availability. Iovance introduced the therapy in the U.S. at a wholesale acquisition cost of <strong>USD 515,000 per patient<\/strong>. After its U.S. launch on February 20, 2024, AMTAGVI generated <strong>USD 103.6 million<\/strong> in product revenue for the year.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"505\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/02\/AMTAGVI-Development-Timeline-1024x505.webp\" alt=\"AMTAGVI-Development-Timeline\" class=\"wp-image-34576\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/02\/AMTAGVI-Development-Timeline-1024x505.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/02\/AMTAGVI-Development-Timeline-300x148.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/02\/AMTAGVI-Development-Timeline-150x74.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/02\/AMTAGVI-Development-Timeline-768x379.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/02\/AMTAGVI-Development-Timeline-1536x758.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/02\/AMTAGVI-Development-Timeline.webp 1920w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p><em>Sadaf Javed, Manager of Forecasting and Analytics at DelveInsight, said that with more than a year into the US launch of AMTAGVI for advanced melanoma, the first FDA-approved TIL cell therapy, the adoption continues to grow. For the first time, AMTAGVI surpassed more than 100 patients treated in a single quarter. The real-world data set for AMTAGVI shows a nearly 49% response rate among 41 patients, and for 23 patients treated in third-line or earlier treatment settings, and approximately 61% response rate, all from patients treated in accordance with the label.<\/em><\/p>\n\n\n\n<p>In November 2025, Iovance Biotherapeutics reported that it expects potential regulatory approvals for AMTAGVI in the U.K. and Australia in the first half of 2026, and in Switzerland in 2027. The company submitted a centralized Marketing Authorization Application (MAA) for lifileucel to the European Medicines Agency in June 2024, which the EMA validated and accepted for review in August 2024. However, Iovance later withdrew the application for melanoma treatment in adults on July 22, 2025.<\/p>\n\n\n\n<p>According to the company\u2019s Q1 2025 presentation, AMTAGVI is listed in the NCCN guidelines as a preferred second-line or later therapy option for cutaneous melanoma. The approval has catalyzed broader investment in TIL platforms and firmly positioned Iovance as the current market leader, while also raising the bar for emerging competitors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-emerging-til-pipeline-next-generation-innovation\"><span class=\"ez-toc-section\" id=\"The_Emerging_TIL_Pipeline_Next%E2%80%91Generation_Innovation\"><\/span><strong>The Emerging TIL Pipeline: Next\u2011Generation Innovation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Following AMTAGVI\u2019s approval, a wave of <a href=\"https:\/\/www.delveinsight.com\/report-store\/tumor-infiltrating-lymphocyte-til-therapies-market-forecast\">next\u2011generation TIL candidates<\/a> is advancing through early\u2011 to mid\u2011stage development. TIL-based therapies under development encompass a range of adoptive cell therapy approaches, including conventional autologous <strong>TIL products<\/strong> (LN-145, CC-38), <strong>next-generation engineered or edited TILs<\/strong> (CISH-inactivated TILs, KSQ-001EX [SOCS1 single-edit eTIL], KSQ-004EX [SOCS1\/Regnase-1 dual-edit eTIL], IOV-3001, and IOV-4001), <strong>cytokine-optimized platforms<\/strong> (OBX-115, an IL-2\u2013sparing engineered TIL therapy), and <strong>highly selected tumor-reactive T-cell populations<\/strong> (AGX148, enriched for CD39\u207aCD103\u207aCD8\u207a cells). These programs aim to improve efficacy, safety, manufacturing efficiency, and patient access.&nbsp;<\/p>\n\n\n\n<p>Key TIL therapy developers, including <strong>Iovance Biotherapeutics, REPROCELL, Curacell Holding, Intima Bioscience, KSQ Therapeutics, Obsidian Therapeutics<\/strong>, and others, are advancing diverse, next-generation platforms, largely targeting melanoma while exploring broader solid tumors; Iovance\u2019s push to position TIL therapy in earlier-line settings could significantly reshape both the treatment landscape and competitive dynamics.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"759\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/02\/Promising-TIL-Therapies-in-Development-1024x759.webp\" alt=\"Promising-TIL-Therapies-in-Development\" class=\"wp-image-34659\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/02\/Promising-TIL-Therapies-in-Development-1024x759.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/02\/Promising-TIL-Therapies-in-Development-300x222.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/02\/Promising-TIL-Therapies-in-Development-150x111.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/02\/Promising-TIL-Therapies-in-Development-768x569.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/02\/Promising-TIL-Therapies-in-Development.webp 1457w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p><em>Sadaf said that TIL therapy developers are primarily targeting the US market, driven by Iovance\u2019s first-in-class approval in the world\u2019s largest commercial market, while development in Asia, particularly Japan, remains limited; ReproCELL\u2019s Phase II program represents an early local effort that, if successful, could leverage lower manufacturing costs and expand treatment options for Japanese patients.<\/em><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-recent-developments-in-the-til-therapy-segment\"><span class=\"ez-toc-section\" id=\"Recent_Developments_in_the_TIL_Therapy_Segment\"><\/span><strong>Recent Developments in the TIL Therapy Segment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<ul class=\"wp-block-list\">\n<li>In <strong>November 2025, Iovance Biotherapeutics (NASDAQ: IOVA) <\/strong>announced that potential approvals of AMTAGVI are anticipated in the United Kingdom and Australia in the first half of 2026 and in Switzerland in 2027.<\/li>\n\n\n\n<li>In <strong>November 2025, Iovance (NASDAQ: IOVA)<\/strong> announced that it expects the IOV-LUN-202 trial to complete enrollment in 2026 and support a supplemental BLA for lifileucel in nonsquamous NSCLC, with a potential launch in 2027.<\/li>\n\n\n\n<li>In <strong>November 2025, Iovance (NASDAQ: IOVA)<\/strong> announced that initial results from the IOV-END-201 clinical trial of lifileucel in previously treated advanced endometrial cancer are on track for early 2026.<\/li>\n\n\n\n<li>In <strong>August 2025, Iovance Biotherapeutics (NASDAQ: IOVA)<\/strong> announced that more than 100 patients were treated with lifileucel in 2Q25. The company also announced that review in the United Kingdom is on track for potential approval and launch in the first half of 2026.<\/li>\n\n\n\n<li>In <strong>June 2025, Obsidian Therapeutics<\/strong> announced initial Phase I safety and efficacy data from the Phase I\/II Agni-01 multicenter study of OBX-115, a novel engineered tumor-derived autologous TIL cell therapy armored with pharmacologically regulatable membrane-bound IL15 (mbIL15), in patients with immune checkpoint inhibitor (ICI)-resistant advanced or metastatic melanoma (NCT06060613).<\/li>\n\n\n\n<li>In <strong>May 2025, Biosyngen<\/strong> announced presentation of BST02 Phase I results at ASCO 2025.<\/li>\n\n\n\n<li>In <strong>April 2025, KSQ Therapeutics<\/strong> announced the first patient dosed in the Phase I\/II clinical study of KSQ-004EX, a novel CRISPR-engineered TIL (eTIL) therapy.<\/li>\n<\/ul>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-conclusion-a-new-era-for-solid-tumor-cell-therapy\"><span class=\"ez-toc-section\" id=\"Conclusion_A_New_Era_for_Solid_Tumor_Cell_Therapy\"><\/span><strong>Conclusion: A New Era for Solid Tumor Cell Therapy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>TIL therapy is ushering in a new era for cell\u2011based treatment of solid tumors, shifting the field from experimental promise to tangible clinical impact. With the approval of AMTAGVI and a rapidly advancing pipeline, these therapies are beginning to redefine expectations for patients who historically had very limited options.<\/p>\n\n\n\n<p>Unlike earlier generations of immunotherapies that often struggle with tumor heterogeneity, TIL products leverage a polyclonal T\u2011cell repertoire capable of recognizing multiple neoantigens and shared tumor antigens. This breadth of recognition positions TILs as a powerful option in complex tumors such as melanoma, NSCLC, cervical, endometrial, and liver cancers, where antigen escape and resistance to checkpoint inhibitors are common. As real\u2011world data accumulate, they are reinforcing the clinical trial signal that TILs can deliver deep and durable responses in heavily pretreated patients.<\/p>\n\n\n\n<p>With a growing pipeline targeting high\u2011burden indications such as NSCLC, melanoma, liver, endometrial, and cervical cancers, the total addressable <a href=\"https:\/\/www.delveinsight.com\/report-store\/tumor-infiltrating-lymphocyte-til-therapies-market-forecast\">TIL therapy market<\/a> in the leading markets is substantial and poised for sustained growth from <strong>USD 103 million<\/strong> in 2024 at a tremendous <strong>CAGR of 37%<\/strong> by 2034.&nbsp;<\/p>\n\n\n\n<p><em>Sadaf further noted that several factors are expected to accelerate the growth of the TIL therapies market during the forecast period (2025\u20132034), including faster and more accurate patient diagnosis, increased clinical and patient awareness, the introduction of emerging TIL therapies, and label expansions to additional indications.<\/em><\/p>\n\n\n\n<p>The next wave of innovation is already in motion, with engineered and \u201carmored\u201d TILs, CRISPR\u2011edited products, and cryopreserved formulations aiming to boost efficacy, simplify logistics, and broaden access. Combination strategies with checkpoint inhibitors, targeted agents, and novel immune modulators are being tested to enhance durability and push TILs into earlier lines of therapy. Success in these areas could expand use beyond ultra\u2011refractory populations and cement TILs as a core component of multimodal treatment paradigms.<\/p>\n\n\n\n<p>Taken together, TIL therapies stand at a pivotal moment: no longer a niche academic curiosity, but not yet fully mature. Their trajectory over the next decade will be shaped by how effectively developers can translate scientific advances into reproducible, efficient, and accessible products. If these challenges are met, TILs have the potential to become a foundational modality in solid tumor oncology, delivering sustained benefit for patients who have long faced poor prognoses and limited hope for long\u2011term control.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/tumor-infiltrating-lymphocyte-til-therapies-market-forecast\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/02\/Tumor\u2011Infiltrating-Lymphocyte-TIL-Therapies-Market-Outlook-1024x194.webp\" alt=\"Tumor\u2011Infiltrating Lymphocyte (TIL) Therapies Market Outlook\" class=\"wp-image-34575\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/02\/Tumor\u2011Infiltrating-Lymphocyte-TIL-Therapies-Market-Outlook-1024x194.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/02\/Tumor\u2011Infiltrating-Lymphocyte-TIL-Therapies-Market-Outlook-300x57.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/02\/Tumor\u2011Infiltrating-Lymphocyte-TIL-Therapies-Market-Outlook-150x28.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/02\/Tumor\u2011Infiltrating-Lymphocyte-TIL-Therapies-Market-Outlook-768x145.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/02\/Tumor\u2011Infiltrating-Lymphocyte-TIL-Therapies-Market-Outlook-1536x291.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/02\/Tumor\u2011Infiltrating-Lymphocyte-TIL-Therapies-Market-Outlook.webp 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Summary&nbsp; Over the past decade, cell-based immunotherapies have revolutionized the treatment landscape for hematologic malignancies. In contrast, solid tumors have remained far more resistant to curative cellular approaches. Tumor-infiltrating lymphocyte (TIL) therapies are now emerging as one of the most promising solutions to this challenge, offering a highly personalized strategy that leverages a patient\u2019s own [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":34573,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[21816,1446,1111,2450,22896,22894,22895],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-34571","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-amtagvi","tag-car-t-therapies","tag-nsclc","tag-solid-tumors","tag-til-therapies","tag-tumorinfiltrating-lymphocyte","tag-tumorinfiltrating-lymphocyte-therapy","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>TIL Therapies: The Next Frontier in Solid Tumor Treatment<\/title>\n<meta name=\"description\" content=\"TIL therapy marks a major shift in solid-tumor immunotherapy, offering an effective approach where CAR-T strategies have struggled.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/til-therapies-for-solid-tumor-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TIL Therapies: The Next Frontier in Solid Tumor Treatment\" \/>\n<meta property=\"og:description\" content=\"TIL therapy marks a major shift in solid-tumor immunotherapy, offering an effective approach where CAR-T strategies have struggled.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/til-therapies-for-solid-tumor-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-20T12:26:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-06T09:56:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/02\/til-therapies-for-solid-tumor-treatment.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"TIL Therapies: The Next Frontier in Solid Tumor Treatment","description":"TIL therapy marks a major shift in solid-tumor immunotherapy, offering an effective approach where CAR-T strategies have struggled.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/til-therapies-for-solid-tumor-treatment","og_locale":"en_US","og_type":"article","og_title":"TIL Therapies: The Next Frontier in Solid Tumor Treatment","og_description":"TIL therapy marks a major shift in solid-tumor immunotherapy, offering an effective approach where CAR-T strategies have struggled.","og_url":"https:\/\/www.delveinsight.com\/blog\/til-therapies-for-solid-tumor-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-02-20T12:26:00+00:00","article_modified_time":"2026-03-06T09:56:58+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/02\/til-therapies-for-solid-tumor-treatment.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/til-therapies-for-solid-tumor-treatment","url":"https:\/\/www.delveinsight.com\/blog\/til-therapies-for-solid-tumor-treatment","name":"TIL Therapies: The Next Frontier in Solid Tumor Treatment","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/til-therapies-for-solid-tumor-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/til-therapies-for-solid-tumor-treatment#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/02\/til-therapies-for-solid-tumor-treatment.webp","datePublished":"2026-02-20T12:26:00+00:00","dateModified":"2026-03-06T09:56:58+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"TIL therapy marks a major shift in solid-tumor immunotherapy, offering an effective approach where CAR-T strategies have struggled.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/til-therapies-for-solid-tumor-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/til-therapies-for-solid-tumor-treatment#primaryimage","url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/02\/til-therapies-for-solid-tumor-treatment.webp","contentUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/02\/til-therapies-for-solid-tumor-treatment.webp","width":466,"height":284,"caption":"til-therapies-for-solid-tumor-treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/02\/til-therapies-for-solid-tumor-treatment-300x183.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Amtagvi<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">CAR-T therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">NSCLC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">solid tumors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">TIL Therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Tumor\u2011Infiltrating Lymphocyte<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Tumor\u2011Infiltrating Lymphocyte Therapy<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Amtagvi<\/span>","<span class=\"advgb-post-tax-term\">CAR-T therapies<\/span>","<span class=\"advgb-post-tax-term\">NSCLC<\/span>","<span class=\"advgb-post-tax-term\">solid tumors<\/span>","<span class=\"advgb-post-tax-term\">TIL Therapies<\/span>","<span class=\"advgb-post-tax-term\">Tumor\u2011Infiltrating Lymphocyte<\/span>","<span class=\"advgb-post-tax-term\">Tumor\u2011Infiltrating Lymphocyte Therapy<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 months ago","modified":"Updated 1 month ago"},"absolute_dates":{"created":"Posted on Feb 20, 2026","modified":"Updated on Mar 6, 2026"},"absolute_dates_time":{"created":"Posted on Feb 20, 2026 5:56 pm","modified":"Updated on Mar 6, 2026 3:26 pm"},"featured_img_caption":"til-therapies-for-solid-tumor-treatment","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34571","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=34571"}],"version-history":[{"count":4,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34571\/revisions"}],"predecessor-version":[{"id":34660,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34571\/revisions\/34660"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/34573"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=34571"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=34571"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=34571"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=34571"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=34571"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}